The latest lymphoma news
ASH 2023: Cell therapy appears safe and effective for lymphoma in remission
A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami…
The latest lymphoma news
A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami…
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University…
The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate…
This content is password protected. To view it please enter your password below: Password:
The National Comprehensive Cancer Network® (NCCN®) today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma…
A growing repertoire of cell and molecule-based immunotherapies is offering patients with indomitable cancers new…
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University…
A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission…
Patient outcomes from an international cooperative clinical trial for advanced stage Hodgkin lymphoma show “the…
The Food and Drug Administration has granted accelerated approval to glofitamab-gxbm for relapsed or refractory…